|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids显示文摘Hepatocellular carcinoma(HCC), with its high incidence and mortality rate, is one of the most common malignant tumors. Despite recent development of a diagnostic and treatment method, the prognosis of HCC remains poor. Therefore, to provide optimal treatment for each patient with HCC, more precise and effective biomarkers are urgently needed which could facilitate a more detailed individualized decision-making during HCC treatment, including the following; risk assessment, early cancer detection, prediction of treatment or prognostic outcome. In the blood of cancer patients, accumulating evidence about circulating tumor cells and cell-free nucleic acids has suggested their potent clinical utilities as novel biomarker. This concept, so-called 'liquid biopsy' is widely known as an alternative approach to cancer tissue biopsy. This method might facilitate a more sensitive diagnosis and better decision-making by obtaining genetic and epigenetic aberrations that are closely associated with cancer initiation and progression. In this article, we review recent developments based on the available literature on both circulating tumor cells and cell-free nucleic acids in cancer patients, especially focusing on Hepatocellular carcinoma. | wataru okajima shuhei komatsu daisuke ichikawa mahito miyamae takuma ohashi taisuke imamura jun kiuchi keiji nishibeppu tomohiro arita hirotaka konishi atsushi shiozaki ryo morimura hisashi ikoma kazuma okamoto eigo otsuji | 2017 | World Journal of Gastroenterology2017，23，31： | 22 |
| 2 | Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids显示文摘Despite recent advances in surgical techniques and perioperative management, the prognosis of pancreatic cancer(PCa) remains extremely poor. To provide optimal treatment for each patient with Pca, superior biomarkers are urgently needed in all phases of management from early detection to staging, treatment monitoring, and prognosis. In the blood of patients with cancer, circulating tumor cells(CTCs) and cell-free nucleic acids(cf NAs), such as DNA, m RNA, and noncoding RNA have been recognized. In the recent years, their presence in the blood has encouraged researchers to investigate their potential use as novel blood biomarkers, and numerous studies have demonstrated their potential clinical utility as a biomarker for certain types of cancer. This concept, called 'liquid biopsy' has been focused on as a less invasive, alternative approach to cancer tissue biopsy for obtaining genetic and epigenetic aberrations that contribute to oncogenesis and cancer progression. In this article, we review the available literature on CTCs and cfN As in patients with cancer, particularly focusing on PCa, and discuss future perspectives in this field. | Taisuke Imamura Shuhei Komatsu Daisuke Ichikawa Tsutomu Kawaguchi Mahito Miyamae Wataru Okajima Takuma Ohashi Tomohiro Arita Hirotaka Konishi Atsushi Shiozaki Ryo Morimura Hisashi Ikoma Kazuma Okamoto Eigo Otsuji | 2016 | World Journal of Gastroenterology2016，22，25： | 10 |
| 3 | Clinical characteristics of hepatoduodenal lymph node metastasis in gastric cancer显示文摘AIM: To assess the clinical features of hepatoduodenal lymph node(HDLN) metastasis and to clarify the optimal indication of HDLN dissection.METHODS: We investigated a total of 276 patients who underwent gastrectomy with extended lymphadenectomy,including HDLN dissection,for gastric cancer between 1999 and 2012. Of these,26 patients(9.4%) had HDLN metastasis. First,we investigated the clinicopathological characteristics,their perioperative clinical outcomes,such as postoperative complications,and prognostic outcomes between patients with and without HDLN metastasis. Second,we detected the prognostic factors,particularly in patients with HDLN metastasis. Third,we assessed the therapeutic value of HDLN dissection to determine its optimal indication.RESULTS: The five-year overall survival rate of the patients with HDLN metastasis was 29%. Univariate and multivariate logistic regression analyses revealed that the tumour location(the middle or lower stomach [P = 0.005,OR = 5.88(95%CI: 1.61-38.1)] and p T category [T3 or T4,P = 0.017,OR = 4.45(95%CI: 1.28-21.3)] were independent risk factors for HDLNmetastasis. Cox proportional hazard analysis identified p N3 as an independent poor prognostic factor in the patients with HDLN metastasis [P = 0.021,HR = 5.17(95%CI: 1.8-292)]. For patients who underwent radical HDLN dissection,HDLN metastasis was a prognostic indicator in p N3 gastric cancer(P < 0.0001),but not p N1-2(P = 0.602). Furthermore,the index of therapeutic value of HDLN dissection for gastric cancer in the middle or lower stomach and the upper stomach was 3.4 and 0.0,respectively.CONCLUSION: We suggest that HDLN dissection should be indicated for p N1 or p N2 gastric cancers located at the middle or lower stomach. | Taisuke Imamura Shuhei Komatsu Daisuke Ichikawa Toshiyuki Kosuga Kazuma Okamoto Hirotaka Konishi Atsushi Shiozaki Hitoshi Fujiwara Eigo Otsuji | 2015 | World Journal of Gastroenterology2015，21，38： | 4 |
| 4 | Gastric carcinoma originating from the heterotopic submucosal gastric gland treated by laparoscopy and endoscopy cooperative surgery显示文摘Gastric carcinoma is derived from epithelial cells in the gastric mucosa. We reported an extremely rare case of submucosal gastric carcinoma originating from the heterotopic submucosal gastric gland(HSG) that was safely diagnosed by laparoscopy and endoscopy cooperative surgery(LECS). A 66-year-old man underwent gastrointestinal endoscopy, which detected a submucosal tumor(SMT) of 1.5 cm in diameter on the lesser-anterior wall of the upper gastric body. The tumor could not be diagnosed histologically, even by endoscopic ultrasound-guided fine-needle aspiration biopsy. Local resection by LECS was performed to confirm a diagnosis. Pathologically, the tumor was an intra-submucosal well differentiated adenocarcinoma invading 5000 μm intothe submucosal layer. The resected tumor had negative lateral and vertical margins. Based on the Japanese treatment guidelines, additional laparoscopic proximal gastrectomy was curatively performed. LECS is a less invasive and safer approach for the diagnosis of SMT, even in submucosal gastric carcinoma originating from the HSG. | Taisuke Imamura Shuhei Komatsu Daisuke Ichikawa Hiroki Kobayashi Mahito Miyamae Shoji Hirajima Tsutomu Kawaguchi Takeshi Kubota Toshiyuki Kosuga Kazuma Okamoto Hirotaka Konishi Atsushi Shiozaki Hitoshi Fujiwara Kiyoshi Ogiso Nobuaki Yagi Akio Yanagisawa Takashi Ando Eigo Otsuji | 2015 | World Journal of Gastrointestinal Oncology2015，7，8： | 1 |
| 5 | Malignant potential in pancreatic neoplasm; new insights provided by circulating miR-223 in plasma显示文摘 | Shuhei Komatsu Daisuke Ichikawa Mahito Miyamae Tsutomu Kawaguchi Ryo Morimura Shoji Hirajima Wataru Okajima Takuma Ohashi Taisuke Imamura Hirotaka Konishi Atsushi Shiozaki Hisashi Ikoma Kazuma Okamoto Hiroki Taniguchi Eigo Otsuji | 2015 | Expert Opinion on Biological Therapy2015，，6： | 1 |
| 6 | Periostin and bone marrow fibrosis显示文摘 | Eijiro Oku Taisuke Kanaji Yuka Takata Koichi Oshima Ritsuko Seki Satoshi Morishige Rie Imamura Korenori Ohtsubo Michitoshi Hashiguchi Koichi Osaki Kazuaki Yakushiji Kohji Yoshimoto Hideaki Ogata Hirofumi Hamada Kenji Izuhara Michio Sata Takashi Okamura | 2008 | International Journal of Hematology2008，，1： | 1 |
| 7 | Genomic alterations in hepatocellular carcinoma and their clinical application to genomic medicine显示文摘Liver cancer remains a global health problem and its incidence is growing worldwide.Liver cancer is an epidemiologically biased disease and is one of the most common cancers,especially in East Asia.Hepatocellular carcinoma(HCC)is the dominant histological type of liver cancer and the principal etiological factor for HCC in Japan is hepatitis C virus(HCV),while that in other Asian countries is hepatitis B virus(HBV)(1).Other known risk factors include alcohol abuse,autoimmune hepatitis,diabetes,and several metabolic diseases.However,the precise molecular events underlying hepatocarcinogenesis are still not fully understood,and the genetic characteristics associated with the etiologies still remain unclear.Recent large-scale genomic analyses have revealed the overall landscape and there are active attempts to apply the results to clinical practice.Based on the latest findings,we will describe the overall landscape of genomic alterations in HCC and their application to genomic medicine. | Taisuke Imamura Yukiyasu Okamura | 2022 | Hepatobiliary Surgery and Nutrition2022，11，3： | 0 |
| 8 | Circulating microRNAs as a liquid biopsy: a next generation clinical biomarker for diagnosis of gastric cancer显示文摘Accumulating evidence has suggested the potential clinical utility of novel body fluid biomarkers,or“liquid biopsy”,using circulating tumor cells and cell-free nucleic acids from cancer patients.Noninvasive and reproducible,liquid biopsy could provide the basis for individualized therapeutic strategies by identifying genetic and epigenetic aberrations that are closely associated with cancer initiation and progression.MicroRNAs(miRNAs)are short noncoding RNAs that post-transcriptionally regulate gene expression.They also play important roles in various physiological and developmental processes as oncogenic or tumor-suppressive regulators.Specific miRNA expression signatures have been identified in a number of human cancers.Circulating miRNAs have been detected in plasma and serum,and this in blood has attracted the attention of researchers for their potential as noninvasive biomarkers.Circulating miRNAs have emerged as tumor-associated biomarkers that reflect not only the existence of cancer,but also the dynamics,malignant potential,and drug resistance of tumors.Herein,we review the recent biological and clinical research on the circulating miRNAs of gastric cancer and discuss future perspectives for their clinical applications as a liquid biopsy. | Shuhei Komatsu Jun Kiuchi Taisuke Imamura Daisuke Ichikawa Eigo Otsuji | 2018 | Journal of Cancer Metastasis and Treatment2018，4，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员